Overview

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

Status:
Completed
Trial end date:
2019-02-16
Target enrollment:
Participant gender:
Summary
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.
Phase:
Phase 3
Details
Lead Sponsor:
Aleor Dermaceuticals Limited
Collaborator:
Catawba Research, LLC
Treatments:
Adapalene